|
Age (“≤65”as reference)
| | |
0.004
| | |
0.000
|
|
66–80
|
1.075
|
0.935–1.236
|
0.311
|
1.285
|
1.123–1.470
|
0.000
|
|
>80
|
1.391
|
1.143–1.694
|
0.001
|
1.977
|
1.643–2.378
|
0.000
|
|
Sex (“Male” as reference)
|
|
Female
|
0.961
|
0.843–1.095
|
0.548
|
0.990
|
0.869–1.129
|
0.885
|
|
Race (“White” as reference)
| | |
0.600
| | |
0.593
|
|
Black
|
0.984
|
0.823–1.177
|
0.863
|
0.962
|
0.805–1.148
|
0.665
|
|
Other
|
0.923
|
0.789–1.079
|
0.313
|
0.923
|
0.791–1.078
|
0.314
|
|
Tumor location (“Cardia” as reference)
| | |
0.008
| | |
0.020
|
|
Non-cardia
|
0.816
|
0.684–0.974
|
0.024
|
0.935
|
0.785–1.113
|
0.449
|
|
Overlapping lesion
|
1.054
|
0.829–1.340
|
0.669
|
1.241
|
0.977–1.577
|
0.077
|
|
Stomach, NOSc
|
1.014
|
0.784–1.312
|
0.915
|
1.129
|
0.876–1.455
|
0.348
|
|
Tumor size (“≤30 mm” as reference)
| | |
0.033
| | |
0.041
|
|
31-50 mm
|
0.985
|
0.802–1.209
|
0.882
|
1.120
|
0.914–1.373
|
0.273
|
|
> 50 mm
|
0.833
|
0.684–1.014
|
0.069
|
0.938
|
0.773–1.138
|
0.515
|
|
Subtype (“Intestinal type” as reference)
| | |
0.536
| | |
0.267
|
|
Diffuse type
|
0.861
|
0.664–1.117
|
0.260
|
0.925
|
0.717–1.193
|
0.547
|
|
Adenocarcinoma, NOS
|
0.997
|
0.846–1.175
|
0.972
|
1.095
|
0.932–1.287
|
0.269
|
|
Other adenocarcinoma
|
0.906
|
0.708–1.159
|
0.431
|
0.943
|
0.738–1.206
|
0.642
|
|
Grade (“Grade1/2” as reference)
|
|
Grade3/4
|
1.334
|
1.155–1.540
|
0.000
|
1.269
|
1.100–1.463
|
0.001
|
|
T category-AJCCd 7th (“T1” as reference)
| | |
0.000
| | |
0.000
|
|
T2
|
1.395
|
0.894–2.179
|
0.143
|
1.252
|
0.803–1.953
|
0.321
|
|
T3
|
1.906
|
1.341–2.708
|
0.000
|
1.658
|
1.171–2.348
|
0.004
|
|
T4a
|
2.284
|
1.594–3.273
|
0.000
|
1.971
|
1.382–2.811
|
0.000
|
|
T4b
|
2.457
|
1.704–3.542
|
0.000
|
2.128
|
1.481–3.058
|
0.000
|
|
N category-AJCC 7th (“N0” as reference)
| | |
0.000
| | | |
|
N1
|
1.341
|
1.082–1.662
|
0.007
|
–
|
–
|
–
|
|
N2
|
2.003
|
1.579–2.542
|
0.000
|
–
|
–
|
–
|
|
N3
|
2.128
|
1.617–2.801
|
0.000
|
–
|
–
|
–
|
|
N+
|
–
|
–
|
–
|
1.397
|
1.137–1.717
|
0.001
|
|
Metastatic site(s) (“Distant LN(s)e” as reference)
| | |
0.000
| | |
0.000
|
|
Viscera
|
1.496
|
1.255–1.783
|
0.000
|
1.586
|
1.334–1.886
|
0.000
|
|
Viscera plus distant LN(s)
|
1.810
|
1.389–2.359
|
0.000
|
1.782
|
1.372–2.314
|
0.000
|
|
Distant metastasis, NOS
|
1.748
|
1.223–2.497
|
0.002
|
1.664
|
1.173–2.362
|
0.004
|
|
Gastrectomy (“Partial gastrectomy” as reference)
| | |
0.078
| | | |
|
Near-total or total gastrectomy
|
0.838
|
0.718–0.978
|
0.025
|
–
|
–
|
–
|
|
Gastrectomy, NOS
|
0.930
|
0.801–1.080
|
0.343
|
–
|
–
|
–
|
|
No. of regional LN(s) examined (“≤10” as reference)
|
|
> 10
|
0.684
|
0.591–0.792
|
0.000
|
–
|
–
|
–
|
|
Surgery to other site(s) or node(s) (“No” as reference
|
|
Yes
|
1.008
|
0.877–1.159
|
0.913
|
–
|
–
|
–
|
|
Chemotherapy (“No/Unknown” as reference
|
|
Yes
|
0.514
|
0.448–0.589
|
0.000
|
–
|
–
|
–
|
|
Radiotherapy (“No/Unknown” as reference
|
|
Yes
|
0.778
|
0.647–0.936
|
0.008
|
–
|
–
|
–
|
